Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C

This publication has 41 references indexed in Scilit:

• Effects of silymarin on hepatitis C virus and haem oxygenase‐1 gene expression in human hepatoma cells
  Liver International, 2009
• Effects of silymarin supplementation in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study
  Orvosi Hetilap, 2009
• Hepatic Metabolism and Biliary Excretion of Silymarin Flavonolignans in Isolated Perfused Rat Livers: Role of Multidrug Resistance-Associated Protein 2 (Abcc2)
  Drug Metabolism and Disposition, 2008
• Peginterferon and Ribavirin for Chronic Hepatitis C
  New England Journal of Medicine, 2006
• Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process
  Journal of Pharmaceutical and Biomedical Analysis, 2004
• Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin
  Phytotherapy Research, 2002
• Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis
  Int. Journal of Clinical Pharmacology and Therapeutics, 2002
• Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1(I) and TIMP-1
  Journal of Hepatology, 2001
• Comparative bioavailability of Silipide, a new flavanolignan complex, in rats
  European Journal of Drug Metabolism and Pharmacokinetics, 1992
• Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
  Journal of Hepatology, 1989